SuperBranche — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

SuperBranche, founded in 2019 and based in Paris, is a private biotech company with a unique theranostic platform centered on its proprietary SUPERSPIO magnetic nanoparticles. The platform combines diagnostic imaging (MRI/MPI) with therapeutic capabilities (magnetic hyperthermia) for oncology, particularly aimed at tracking innovative cell therapies and treating solid tumors. The company is in the preclinical stage with its lead candidate, SPB-20X1, recently secured €13 million in funding, and is constructing a GMP pilot production facility in Sélestat, France. SuperBranche leverages open innovation through collaborations with research institutes and industrial partners.

Oncology

Technology Platform

Proprietary SUPERSPIO magnetic nanoparticle platform enabling non-ionizing MRI/MPI imaging, quantitative MPI, targeted magnetic hyperthermia therapy, and in vivo tracking of cell therapies (e.g., stem cells, extracellular vesicles).

Opportunities

The growing market for theranostics and personalized oncology presents a major opportunity.

Additionally, the critical unmet need for non-invasive tracking of cell and gene therapies creates a near-term service-based revenue stream through collaborations with biopharma companies developing these advanced therapies.

Risk Factors

Key risks include the high technical and clinical uncertainty of moving a novel theranostic platform from preclinical to human trials, complex regulatory pathways for combination products, challenges in scaling GMP manufacturing of nanoparticles, and competition in the magnetic nanoparticle and cell tracking spaces.

Competitive Landscape

SuperBranche competes in the emerging field of magnetic nanoparticle-based theranostics. Competitors include other nanomedicine companies developing iron oxide particles for imaging or hyperthermia. Its cell tracking platform faces competition from alternative imaging modalities (e.g., nuclear, optical) and other magnetic labeling technologies. Differentiation hinges on the unique 'super-branched' synthesis, quantitative MPI capability, and dual imaging/therapy functionality.

More companies in Diagnostics & Precision Medicine →More companies in France →